Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
9 Tips for Avoiding Tax Season Cyber Scams 
Johnson & Johnson may be divided soon as there are plans to split it to become two separate companies. With the division, one will operate the pharmaceutical business while the other will be for the consumer products.
Johnson & Johnson revealed its plans to split up its consumer products and medical device operations late last week. It said it would be forming two publicly traded companies, and this news reportedly triggered an increase in the company’s shares after the figures went higher in premarket trading.
The move will separate J&J’s household products unit that makes leading brands such as Neutrogena, Aveeno, and Listerine, from its unit that makes and sells medical devices like AI and robotics and prescription drugs, including the COVID-19 vaccine.
The separation process is expected to be completed within 18 to 24 months. Based on the reports, the medical device unit will be retaining the Johnson & Johnson brand name, and the incoming chief executive officer, Joaquin Duato, will be leading this newly-formed company.
CNBC reported that for the consumer side of the business, outgoing CEO, Alex Gorsky, said they have not decided on its name yet.
“Following a comprehensive review, the board and management team believe that the planned separation of the consumer health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth,” Gorsky said in a statement regarding the split of the firm. “Most importantly – improve healthcare outcomes for people around the world.”
He added that the decision to separate the company into two was approved by the board after discussions that have been going on for some time already. They concluded it was a good step to take because they think it would bring numerous opportunities to stakeholders.
As per Los Angeles Times, the executives of Johnson & Johnson told analysts that the split of the company would make each business more adept in adapting to its respective markets. Gorsky stated the division will also address segments that “have evolved as fundamentally different businesses.” Meanwhile, Duato is set to replace Gorsky as CEO in January 2022.
